Page last updated: 2024-10-16

carbamates and Chronic Insomnia

carbamates has been researched along with Chronic Insomnia in 14 studies

Research Excerpts

Excerpt	Relevance	Reference
" Pitolisant, a novel histamine-3 receptor antagonist/inverse agonist, gained approval for the treatment of excessive daytime sleepiness in adults with narcolepsy as well as obstructive sleep apnea."	5.05	New pharmacologic agents for insomnia and hypersomnia. ( Earl, DC; Van Tyle, KM, 2020)
" Using plasma gabapentin concentration data obtained after administration of GEn in 12 phase 1 to 3 GEn studies in healthy adults or patients with RLS (dose range, 300-2400 mg/d), a population pharmacokinetic (PK) model was developed by nonlinear mixed-effect modeling using NONMEM."	2.78	Population pharmacokinetics and pharmacodynamics of gabapentin after administration of gabapentin enacarbil. ( Cundy, KC; Lal, R; Lassauzet, ML; Luo, W; Sukbuntherng, J; Tovera, J, 2013)

Research

Studies (14)

Timeframe	Studies, this research(%)	All Research%
pre-1990	9 (64.29)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (7.14)	29.6817
2010's	3 (21.43)	24.3611
2020's	1 (7.14)	2.80

Authors

Authors	Studies
Earl, DC	1
Van Tyle, KM	1
Sax, PE	1
Wohl, D	1
Yin, MT	1
Post, F	1
DeJesus, E	1
Saag, M	1
Pozniak, A	1
Thompson, M	1
Podzamczer, D	1
Molina, JM	1
Oka, S	1
Koenig, E	1
Trottier, B	1
Andrade-Villanueva, J	1
Crofoot, G	1
Custodio, JM	1
Plummer, A	1
Zhong, L	1
Cao, H	1
Martin, H	1
Callebaut, C	1
Cheng, AK	1
Fordyce, MW	1
McCallister, S	1
Stern, R	1
Hametner, S	1
Ramona, AZ	1
Moser, S	1
Karpi, A	1
Laferl, H	1
Stauber, RE	1
Zoller, HM	1
Maieron, A	1
Vogel, W	1
Graziadei, I	1
Gschwantler, M	1
Kozbial, K	1
Freissmuth, C	1
Hofer, H	1
Ferenci, P	1
Kushida, CA	1
Becker, PM	1
Ellenbogen, AL	1
Canafax, DM	1
Barrett, RW	1
Lal, R	1
Sukbuntherng, J	1
Luo, W	1
Tovera, J	1
Lassauzet, ML	1
Cundy, KC	1
GRUBER, CM	1
GILLHESPY, RO	1
CANLORBE, P	1
BORNICHE, P	1
DARBELLAY, J	1
de Oliveira, JM	1
Lehmann, HE	1
Ban, TA	1
Rickels, K	1
Rosenfeld, H	1
Schneider, B	1
Silverman, HA	1
Wagner, IG	1
Ayd, FJ	1
Bratfos, O	1
Lingjaerde, O	1
Salvesen, C	1

Clinical Trials (3)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Trea[NCT01780506]	Phase 3	872 participants (Actual)	Interventional	2012-12-26	Completed
A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treat[NCT01797445]	Phase 3	872 participants (Actual)	Interventional	2013-03-12	Completed
Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (Genvoya) as Maintenance Treatment of HIV-1/Hepatitis B Virus (HBV)-Coinfected Patients: an Observational Study[NCT03425994]		275 participants (Actual)	Observational [Patient Registry]	2018-02-06	Active, not recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change From Baseline in CD4+ Cell Count at Week 144

(NCT01780506)
Timeframe: Baseline; Week 144

Intervention	cells/µL (Mean)
E/C/F/TAF	323
E/C/F/TDF	310

Change From Baseline in CD4+ Cell Count at Week 48

(NCT01780506)
Timeframe: Baseline; Week 48

Intervention	cells/µL (Mean)
E/C/F/TAF	235
E/C/F/TDF	221

Change From Baseline in CD4+ Cell Count at Week 96

(NCT01780506)
Timeframe: Baseline; Week 96

Intervention	cells/µL (Mean)
E/C/F/TAF	285
E/C/F/TDF	271

Change From Baseline in Serum Creatinine at Week 144

(NCT01780506)
Timeframe: Baseline; Week 144

Intervention	mg/dL (Mean)
E/C/F/TAF	0.04
E/C/F/TDF	0.08

Change From Baseline in Serum Creatinine at Week 48

(NCT01780506)
Timeframe: Baseline; Week 48

Intervention	mg/dL (Mean)
E/C/F/TAF	0.08
E/C/F/TDF	0.11

Change From Baseline in Serum Creatinine at Week 96

(NCT01780506)
Timeframe: Baseline; Week 96

Intervention	mg/dL (Mean)
E/C/F/TAF	0.05
E/C/F/TDF	0.07

Percent Change From Baseline in Hip BMD at Week 144

Hip BMD was assessed by DXA scan. (NCT01780506)
Timeframe: Baseline; Week 144

Intervention	percent change (Mean)
E/C/F/TAF	-0.826
E/C/F/TDF	-3.475

Percent Change From Baseline in Hip BMD at Week 96

Hip BMD was assessed by DXA scan. (NCT01780506)
Timeframe: Baseline; Week 96

Intervention	percent change (Mean)
E/C/F/TAF	-0.951
E/C/F/TDF	-3.515

Percent Change From Baseline in Hip Bone Mineral Density (BMD) at Week 48

Hip BMD was assessed by dual energy x-ray absorptiometry (DXA) scan. (NCT01780506)
Timeframe: Baseline; Week 48

Intervention	percent change (Mean)
E/C/F/TAF	-0.865
E/C/F/TDF	-3.200

Percent Change From Baseline in Spine BMD at Week 144

Spine BMD was assessed by DXA scan. (NCT01780506)
Timeframe: Baseline; Week 144

Intervention	percent change (Mean)
E/C/F/TAF	-0.809
E/C/F/TDF	-3.023

Percent Change From Baseline in Spine BMD at Week 48

Spine BMD was assessed by DXA scan. (NCT01780506)
Timeframe: Baseline; Week 48

Intervention	percent change (Mean)
E/C/F/TAF	-1.337
E/C/F/TDF	-2.956

Percent Change From Baseline in Spine BMD at Week 96

Spine BMD was assessed by DXA scan. (NCT01780506)
Timeframe: Baseline; Week 96

Intervention	percent change (Mean)
E/C/F/TAF	-0.907
E/C/F/TDF	-3.053

Percent Change From Baseline in Urine Beta-2-microglobulin to Creatinine Ratio at Week 144

Urine Beta-2-microglobulin is a renal biomarker which is used to detect drug-induced kidney injury. (NCT01780506)
Timeframe: Baseline; Week 144

Intervention	percent change (Median)
E/C/F/TAF	-24.6
E/C/F/TDF	60.4

Percent Change From Baseline in Urine Beta-2-microglobulin to Creatinine Ratio at Week 48

Urine Beta-2-microglobulin is a renal biomarker which is used to detect drug-induced kidney injury. (NCT01780506)
Timeframe: Baseline; Week 48

Intervention	percent change (Median)
E/C/F/TAF	-32.8
E/C/F/TDF	18.0

Percent Change From Baseline in Urine Beta-2-microglobulin to Creatinine Ratio at Week 96

Urine Beta-2-microglobulin is a renal biomarker which is used to detect drug-induced kidney injury. (NCT01780506)
Timeframe: Baseline; Week 96

Intervention	percent change (Median)
E/C/F/TAF	-33.5
E/C/F/TDF	32.5

Percent Change From Baseline in Urine RBP to Creatinine Ratio at Week 144

Urine RBP is a renal biomarker which is used to detect drug-induced kidney injury. (NCT01780506)
Timeframe: Baseline; Week 144

Intervention	percent change (Median)
E/C/F/TAF	37.4
E/C/F/TDF	106.9

Percent Change From Baseline in Urine RBP to Creatinine Ratio at Week 96

Urine RBP is a renal biomarker which is used to detect drug-induced kidney injury. (NCT01780506)
Timeframe: Baseline; Week 96

Intervention	percent change (Median)
E/C/F/TAF	11.3
E/C/F/TDF	75.0

Percent Change From Baseline in Urine Retinol Binding Protein (RBP) to Creatinine Ratio at Week 48

Urine RBP is a renal biomarker which is used to detect drug-induced kidney injury. (NCT01780506)
Timeframe: Baseline; Week 48

Intervention	percent change (Median)
E/C/F/TAF	6.9
E/C/F/TDF	51.2

Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48

The percentage of participants achieving HIV-1 RNA < 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT01780506)
Timeframe: Week 48

Intervention	percentage of participants (Number)
E/C/F/TAF	93.1
E/C/F/TDF	92.8

Percentage of Participants Experiencing Treatment-emergent Proteinuria Through Week 144

Grades 1 (mild), 2 (moderate), and 3 (severe) were the highest treatment-emergent postbaseline grades for urine protein using the dipstick method. The worst postbaseline value is presented for each participant. (NCT01780506)
Timeframe: Up to 144 weeks

Intervention	percentage of participants (Number)
	Grade 1	Grade 2	Grade 3
E/C/F/TAF	31.3	6.0	0.2
E/C/F/TDF	37.1	7.0	0.2

Percentage of Participants Experiencing Treatment-emergent Proteinuria Through Week 48

Intervention	percentage of participants (Number)
	Grade 1	Grade 2	Grade 3
E/C/F/TAF	25.8	4.6	0
E/C/F/TDF	32.3	4.9	0.2

Percentage of Participants Experiencing Treatment-emergent Proteinuria Through Week 96

Intervention	percentage of participants (Number)
	Grade 1	Grade 2	Grade 3
E/C/F/TAF	28.8	5.1	0.2
E/C/F/TDF	33.9	5.8	0.2

Percentage of Participants With HIV-1 RNA < 20 Copies/mL at Weeks 48, 96, and 144

The percentage of participants achieving HIV-1 RNA < 20 copies/mL at Weeks 48, 96, and 144 were analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT01780506)
Timeframe: Weeks 48, 96. and 144

Intervention	percentage of participants (Number)
	Week 48	Week 96	Week 144
E/C/F/TAF	86.4	84.4	84.6
E/C/F/TDF	87.3	83.6	80.1

Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Weeks 96 and 144

The percentage of participants achieving HIV-1 RNA < 50 copies/mL at Weeks 96 and 144 were analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT01780506)
Timeframe: Weeks 96 and 144

Intervention	percentage of participants (Number)
	Week 96	Week 144
E/C/F/TAF	89.2	86.9
E/C/F/TDF	88.2	83.1

Change From Baseline in CD4+ Cell Count at Week 48

(NCT01797445)
Timeframe: Baseline; Week 48

Intervention	cells/µL (Mean)
E/C/F/TAF	225
E/C/F/TDF	200

Change From Baseline in CD4+ Cell Count at Week 96

(NCT01797445)
Timeframe: Baseline; Week 96

Intervention	cells/µL (Mean)
E/C/F/TAF	274
E/C/F/TDF	260

Change From Baseline in Serum Creatinine at Week 48

(NCT01797445)
Timeframe: Baseline; Week 48

Intervention	mg/dL (Mean)
E/C/F/TAF	0.08
E/C/F/TDF	0.12

Change From Baseline in Serum Creatinine at Week 96

(NCT01797445)
Timeframe: Baseline; Week 96

Intervention	mg/dL (Mean)
E/C/F/TAF	0.04
E/C/F/TDF	0.07

Percent Change From Baseline in Hip BMD at Week 96

Hip BMD was assessed by DXA scan. (NCT01797445)
Timeframe: Baseline; Week 96

Intervention	percent change (Mean)
E/C/F/TAF	-0.364
E/C/F/TDF	-3.023

Percent Change From Baseline in Hip Bone Mineral Density (BMD) at Week 48

Hip BMD was assessed by dual energy x-ray absorptiometry (DXA) scan. (NCT01797445)
Timeframe: Baseline; Week 48

Intervention	percent change (Mean)
E/C/F/TAF	-0.420
E/C/F/TDF	-2.603

Percent Change From Baseline in Spine BMD at Week 48

Spine BMD was assessed by DXA scan. (NCT01797445)
Timeframe: Baseline; Week 48

Intervention	percent change (Mean)
E/C/F/TAF	-1.278
E/C/F/TDF	-2.759

Percent Change From Baseline in Spine BMD at Week 96

Spine BMD was assessed by DXA scan. (NCT01797445)
Timeframe: Baseline; Week 96

Intervention	percent change (Mean)
E/C/F/TAF	-1.017
E/C/F/TDF	-2.516

Percent Change From Baseline in Urine Beta-2-microglobulin to Creatinine Ratio at Week 48

Urine Beta-2-microglobulin is a renal biomarker which is used to detect drug-induced kidney injury. (NCT01797445)
Timeframe: Baseline; Week 48

Intervention	percent change (Median)
E/C/F/TAF	-29.3
E/C/F/TDF	32.3

Percent Change From Baseline in Urine Beta-2-microglobulin to Creatinine Ratio at Week 96

Urine Beta-2-microglobulin is a renal biomarker which is used to detect drug-induced kidney injury. (NCT01797445)
Timeframe: Baseline; Week 96

Intervention	percent change (Median)
E/C/F/TAF	-31.0
E/C/F/TDF	35.2

Percent Change From Baseline in Urine RBP to Creatinine Ratio at Week 96

Urine RBP is a renal biomarker which is used to detect drug-induced kidney injury. (NCT01797445)
Timeframe: Baseline; Week 96

Intervention	percent change (Median)
E/C/F/TAF	16.9
E/C/F/TDF	73.7

Percent Change From Baseline in Urine Retinol Binding Protein (RBP) to Creatinine Ratio at Week 48

Urine RBP is a renal biomarker which is used to detect drug-induced kidney injury. (NCT01797445)
Timeframe: Baseline; Week 48

Intervention	percent change (Median)
E/C/F/TAF	13.3
E/C/F/TDF	51.7

Percentage of Participants Achieving HIV-1 RNA < 50 Copies/mL at Week 48

Intervention	percentage of participants (Number)
E/C/F/TAF	91.6
E/C/F/TDF	88.5

Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 96

The percentage of participants achieving HIV-1 RNA < 50 copies/mL at Week 96 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT01797445)
Timeframe: Week 96

Intervention	percentage of participants (Number)
E/C/F/TAF	84.0
E/C/F/TDF	82.3

Percentage of Participants With HIV-1 RNA < 20 Copies/mL at Weeks 48 and 96

The percentage of participants achieving HIV-1 RNA < 20 copies/mL at Weeks 48 and 96 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT01797445)
Timeframe: Weeks 48 and 96

Intervention	percentage of participants (Number)
	Week 48	Week 96
E/C/F/TAF	82.4	78.7
E/C/F/TDF	80.7	76.8

Percentage of Participants With Treatment-emergent Proteinuria Through Week 48

Intervention	percentage of participants (Number)
	Grade 1	Grade 2	Grade 3
E/C/F/TAF	27.3	4.7	0
E/C/F/TDF	31.6	4.6	0

Percentage of Participants With Treatment-emergent Proteinuria Through Week 96

Intervention	percentage of participants (Number)
	Grade 1	Grade 2	Grade 3
E/C/F/TAF	31.8	5.4	0
E/C/F/TDF	36.9	5.1	0

Reviews

2 reviews available for carbamates and Chronic Insomnia

Article	Year
New pharmacologic agents for insomnia and hypersomnia. Current opinion in pulmonary medicine, 2020, Volume: 26, Issue:6 Topics: Azepines; Carbamates; Dementia; Disorders of Excessive Somnolence; GABA-A Receptor Agonists; Humans;	2020
Pharmacotherapy of tension and anxiety. Current psychiatric therapies, 1972, Volume: 12 Topics: Anxiety; Automobile Driving; Carbamates; Cerebral Cortex; Clinical Trials as Topic; Depression; Dibe	1972

Trials

7 trials available for carbamates and Chronic Insomnia

Article	Year
Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials. Lancet (London, England), 2015, Jun-27, Volume: 385, Issue:9987 Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Arthralgia; Bone Density; Carbamates; CD4 Lymphocyte Count	2015
Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials. Lancet (London, England), 2015, Jun-27, Volume: 385, Issue:9987 Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Arthralgia; Bone Density; Carbamates; CD4 Lymphocyte Count	2015
Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials. Lancet (London, England), 2015, Jun-27, Volume: 385, Issue:9987 Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Arthralgia; Bone Density; Carbamates; CD4 Lymphocyte Count	2015
Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials. Lancet (London, England), 2015, Jun-27, Volume: 385, Issue:9987 Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Arthralgia; Bone Density; Carbamates; CD4 Lymphocyte Count	2015
Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials. Lancet (London, England), 2015, Jun-27, Volume: 385, Issue:9987 Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Arthralgia; Bone Density; Carbamates; CD4 Lymphocyte Count	2015
Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials. Lancet (London, England), 2015, Jun-27, Volume: 385, Issue:9987 Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Arthralgia; Bone Density; Carbamates; CD4 Lymphocyte Count	2015
Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials. Lancet (London, England), 2015, Jun-27, Volume: 385, Issue:9987 Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Arthralgia; Bone Density; Carbamates; CD4 Lymphocyte Count	2015
Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials. Lancet (London, England), 2015, Jun-27, Volume: 385, Issue:9987 Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Arthralgia; Bone Density; Carbamates; CD4 Lymphocyte Count	2015
Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials. Lancet (London, England), 2015, Jun-27, Volume: 385, Issue:9987 Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Arthralgia; Bone Density; Carbamates; CD4 Lymphocyte Count	2015
Randomized, double-blind, placebo-controlled study of XP13512/GSK1838262 in patients with RLS. Neurology, 2009, Feb-03, Volume: 72, Issue:5 Topics: Adult; Amines; Anti-Anxiety Agents; Carbamates; Central Nervous System; Cyclohexanecarboxylic Acids;	2009
Population pharmacokinetics and pharmacodynamics of gabapentin after administration of gabapentin enacarbil. Journal of clinical pharmacology, 2013, Volume: 53, Issue:1 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amines; Carbamates; Cyclohexanecarboxylic Acids; Female;	2013
Pharmacotherapy of tension and anxiety. Current psychiatric therapies, 1972, Volume: 12 Topics: Anxiety; Automobile Driving; Carbamates; Cerebral Cortex; Clinical Trials as Topic; Depression; Dibe	1972
A comparative evaluation of two hypnotic agents in genral practice patients with insomnia. Current therapeutic research, clinical and experimental, 1972, Volume: 14, Issue:6 Topics: Carbamates; Clinical Trials as Topic; Evaluation Studies as Topic; Family Practice; Female; Humans;	1972
A clinical evaluation of the hypnotic efficacy and safety of mebutamate. Diseases of the nervous system, 1972, Volume: 33, Issue:10 Topics: Adult; Aged; Anxiety Disorders; Bipolar Disorder; Blood Pressure; Carbamates; Dose-Response Relation	1972
Symptomatic relief of neurotic symptoms with tybamate: a doube-blind, placebo-controlled study. Acta psychiatrica Scandinavica, 1967, Volume: 43, Issue:3 Topics: Adult; Aged; Anxiety; Carbamates; Clinical Trials as Topic; Depression; Female; Humans; Hysteria; Ma	1967

Other Studies

6 other studies available for carbamates and Chronic Insomnia

Article	Year
Interferon/Ribavirin-Free Antiviral Treatment in Septuagenarians and Octogenarians With Chronic Hepatitis C. The American journal of gastroenterology, 2016, Volume: 111, Issue:5 Topics: Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Carbamates; Drug Therapy, Combination; Fa	2016
Treatment of insomnia with special reference to valmid. The Journal of the Indiana State Medical Association, 1956, Volume: 49, Issue:1 Topics: Carbamates; Health Services; Humans; Hypnotics and Sedatives; Sleep Initiation and Maintenance Disor	1956
Methylpentynol carbamate in the management of insomnia and parkinsonism. The British journal of clinical practice, 1958, Volume: 12, Issue:3 Topics: Anxiety; Carbamates; Humans; Parkinson Disease; Parkinsonian Disorders; Sleep Initiation and Mainten	1958
[Pediatric indications for a synthetic non-barbituric hypnotic: hexapropymate]. Annales de pediatrie, 1962, Dec-02, Volume: 9 Topics: Carbamates; Humans; Hypnotics and Sedatives; Pediatrics; Sleep Initiation and Maintenance Disorders	1962
[THE ORTHONEUROTIC EMYLCAMATE IN DAILY PRACTICE]. Bruxelles medical, 1963, Oct-06, Volume: 43 Topics: Alcoholism; Anxiety; Anxiety Disorders; Automobiles; Carbamates; Cats; Depression; Geriatrics; Mice;	1963
[Effects of pyridinocarbamate in chronic cerebral arteriosclerosis]. Hospital (Rio de Janeiro, Brazil), 1970, Volume: 77, Issue:2 Topics: Aged; Carbamates; Depression; Female; Humans; Intracranial Arteriosclerosis; Male; Mental Fatigue; M	1970